Excellent Preclinical Efficacy Data of Apogenix’ HERA-GITRL Published in Journal for ImmunoTherapy of Cancer
HERA-GITRL Shows Strong Single-Agent Anti-Tumor Activity in Vitro and in Vivo and is Superior to Bivalent Clinical Benchmark Antibody
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in Journal for ImmunoTherapy of Cancer1 demonstrate the potent anti-tumor efficacy of Apogenix’ HERA-GITRL. HERA-GITRL is a hexavalent GITR receptor agonist that acts directly on immune cells, thereby enhancing their anti-tumor immunity. GITR is an especially important target for immunotherapy as GITR signaling provides co-stimulatory signals to boost T cell activation, differentiation, survival, and memory formation.